[限時領取白皮書] Lonza Shapes Biotherapeutics Development Programs Around Different CMC Paths

[限時領取白皮書] Lonza Shapes Biotherapeutics Development Programs Around Different CMC Paths

隨著蛋白質工程和製造技術的發展,小型生物技術公司就和大型製藥公司一樣需要有彈性及客製化的策略去平衡費用、速度和加速藥物開發的風險,以及解決未被滿足的醫療需求之生物治療的許可。

活動介紹

Lonza Shapes Biotherapeutics Development Programs Around Different CMC Paths

依照不同的CMC途徑打造生物治療開發計畫

 

隨著蛋白質工程和製造技術的發展,小型生物技術公司就和大型製藥公司一樣需要有彈性及客製化的策略去平衡費用、速度和加速藥物開發的風險,以及解決未被滿足的醫療需求之生物治療的許可。
As protein engineering and manufacturing technologies evolve, small biotech and major pharma companies alike need flexible, customized strategies that balance cost, speed and risk to accelerate drug development and approval of biotherapeutics that could address unmet medical needs.
 

領取白皮書了解更多!

於網站填寫姓名、公司等基本資料後即可下載

活動議程

Shaped Around You

★40 years’ experience in cell line development
★Flexibility of approach with a solid 100% success rate for 20+ years in IND-enabling CMC modules
★Customizable drug substance and drug product DNA-to-IND programs

During drug development, it is critical to balance risk with time and costs. We understand the complexity of building such optimal paths. By offering flexibility on your journey to IND, we can shape our process around your molecule’s profile, critical milestones and company’s needs.

Our flexibility extends to commercial terms, enhanced portability and specific program guarantees. Giving you even more reasons to choose Lonza. The people powering biologics.

3 Reasons to Partner with Lonza

1. More Flexible
-Integrated drug substance and drug product DNA-to-IND programs for any molecule type.
-Step-by-step approach if you’re not ready to go the distance.
-Access Lonza expertise and global state-of-the-art capabilities to accelerate your drug development with a quality outcome.
-Our capabilities are yours whenever and however you need them.
2. More Committed
-We strive to build valued relations around your critical milestones and needs.
-We customize our programs and proactively solve problems to ensure you reach your IND milestone.
-Dedicated experts with a 100% success rate for 20+ years in IND-enabling CMC modules.
3. More Competitive Than Ever
-Flexible commercial terms.
-Enhanced portability.
-Commercial guarantees for mAbs DNA-to-IND programs.
-Highly experienced technical oversight for new molecular formats.